4577 — Daito Pharmaceutical Co Balance Sheet
0.000.00%
- ¥36bn
- ¥46bn
- ¥51bn
- 60
- 71
- 93
- 90
Annual balance sheet for Daito Pharmaceutical Co, fiscal year end - May 31st, JPY millions except per share, conversion factor applied.
2021 May 31st | 2022 May 31st | 2023 May 31st | 2024 May 31st | 2025 May 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
| Standards: | — | JAS | JAS | JAS | JAS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 3,373 | 4,381 | 3,607 | 2,727 | 2,207 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 12,791 | 16,146 | 17,654 | 16,733 | 20,254 |
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 32,430 | 37,909 | 40,663 | 41,460 | 41,708 |
| Net Property, Plant And Equipment | 21,372 | 23,116 | 25,837 | 31,972 | 31,826 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 57,739 | 64,939 | 70,552 | 77,708 | 78,004 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 12,859 | 14,069 | 15,428 | 18,505 | 17,049 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 16,120 | 17,632 | 19,880 | 25,639 | 26,001 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 41,619 | 47,307 | 50,672 | 52,069 | 52,003 |
| Total Liabilities & Shareholders' Equity | 57,739 | 64,939 | 70,552 | 77,708 | 78,004 |
| Total Common Shares Outstanding |